News
ADC Therapeutics has pulled the drug candidate from development, leaving it with one remaining clinical asset.
Nuvig Therapeutics has dosed the first subject in its Phase II INVGOR trial of NVG-2089 for individuals with CIDP.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback